LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

Kodu・Aktsiate loetelu・CorMedix Inc

CorMedix Inc

Suletud

SektorTervishoid

7.93 -1.25

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

7.83

Max

8.08

Põhinäitajad
By Trading Economics
Sissetulek	-95M 14M
Müük	24M 129M
P/E Sektori keskmine	3.816 49.8
Aktsiakasum	0.16
Kasumimarginaal	10.901
Töötajad	191
EBITDA	9.2M 66M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+77.88% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	14. mai 2026

Turustatistika
By TradingEconomics
Turukapital	52M 620M
Eelmine avamishind	9.18
Eelmine sulgemishind	7.93

Uudiste sentiment

By Acuity

50%

166 / 347 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Strong Bullish Evidence

9.2 / N/A Toetus ja vastupanu

CorMedix Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

7. mai 2026, 23:58 UTC

Tulu

OCBC's First-Quarter Net Profit Rose on Record Noninterest Income

7. mai 2026, 22:57 UTC

Tulu

Australia's Macquarie Beats Consensus With 30% Fiscal Year Profit Jump

7. mai 2026, 23:52 UTC

Tulu

CoreWeave Stock Dives on Weak Outlook -- Barrons.com

7. mai 2026, 23:45 UTC

Market Talk

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

7. mai 2026, 23:39 UTC

Market Talk

Gold Rises on Signs of Ongoing U.S.-Iran Tensions -- Market Talk

7. mai 2026, 23:28 UTC

Market Talk

Australian Budget Set to Contain A$64B in Spending Cuts-- Market Talk

7. mai 2026, 23:11 UTC

Tulu

OCBC Group CEO: Well-Positioned to Navigate Uncertainties, Deliver Sustainable Long-Term Value >O39.SG

7. mai 2026, 23:06 UTC

Tulu

Oversea-Chinese Banking Corp. 1Q Net Interest Margin 1.76%, Down 28 Bps on Year >O39.SG

7. mai 2026, 23:05 UTC

Tulu

Oversea-Chinese Banking Corp.: Solid 1Q Performance Underpinned by Record Non-Interest Income >O39.SG

7. mai 2026, 23:04 UTC

Tulu

Oversea-Chinese Banking Corp. 1Q Non-Interest Income S$1.61B Vs. S$1.31B >O39.SG

7. mai 2026, 23:03 UTC

Tulu

Oversea-Chinese Banking Corp. 1Q Net Interest Income S$2.22B Vs. S$2.35B >O39.SG

7. mai 2026, 23:03 UTC

Tulu

Oversea-Chinese Banking Corp. 1Q Net S$1.97B Vs. Net S$1.88B >O39.SG

7. mai 2026, 23:02 UTC

Tulu

Oversea-Chinese Banking Corp. 1Q Total Income S$3.83B Vs. S$3.66B >O39.SG

7. mai 2026, 23:00 UTC

Market Talk

Australia's Federal Budget Likely to Contain Significant Reforms -- Market Talk

7. mai 2026, 22:45 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

7. mai 2026, 22:45 UTC

Market Talk

Lyft Says Efforts to Service Waymo's AVs Are Underway -- Market Talk

7. mai 2026, 22:42 UTC

Tulu

Australia's Macquarie Beats Consensus With 30% FY Profit Jump

7. mai 2026, 22:33 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Gilead Stock Falls. A Massive Acquisition Spree Is Coming at a Cost. -- Barrons.com

7. mai 2026, 22:32 UTC

Tulu

Macquarie FY Total Customer Deposits A$221.5B Vs. A$177.7B>MQG.AU

7. mai 2026, 22:31 UTC

Tulu

Macquarie FY Return on Equity 14.0% Vs. 11.2%>MQG.AU

7. mai 2026, 22:31 UTC

Tulu

Macquarie: 68% of FY Income From International >MQG.AU

7. mai 2026, 22:30 UTC

Tulu

Macquarie Bank Year-End CET1 Level 2 Ratio 12.8%>MQG.AU

7. mai 2026, 22:30 UTC

Tulu

Macquarie Capital Surplus A$9.3B at March 31 Vs. A$9.5B a Year Earlier>MQG.AU

7. mai 2026, 22:29 UTC

Tulu

Macquarie CEO: Well-Positioned for Superior Medium-Term Performance>MQG.AU

7. mai 2026, 22:28 UTC

Tulu

Macquarie: Continues a Conservative Approach to Capital, Funding, Liquidity>MQG.AU

7. mai 2026, 22:28 UTC

Tulu

Macquarie: Continues to Maintain a Cautious Stance>MQG.AU

7. mai 2026, 22:27 UTC

Tulu

Macquarie: Decision Recognizes Prevailing Market Conditions>MQG.AU

7. mai 2026, 22:27 UTC

Tulu

Macquarie Has Not Purchased Shares Since Extending the Buyback>MQG.AU

7. mai 2026, 22:26 UTC

Tulu

Macquarie to End Share Buyback Extended in November>MQG.AU

7. mai 2026, 22:25 UTC

Tulu

Macquarie Commodities and Global Markets FY Net Profit Contribution A$4.2B, Up 49% on Year>MQG.AU

Võrdlus sarnastega

Hinnamuutus

CorMedix Inc Prognoos

Hinnasiht

By TipRanks

77.88% tõus

12 kuu keskmine prognoos

Keskmine 13.75 USD 77.88%

Kõrge 15 USD

Madal 13 USD

Põhineb 5 Wall Streeti analüütiku instrumendi CorMedix Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

5 ratings

Osta

Hoia

Müü

Põhineb 5 analüütiku instrumendi CorMedix Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

9.2 / N/AToetus ja vastupanu

Recent bullish events outweigh bearish events.

All events are bullish.

Sentiment

By Acuity

166 / 347 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest CorMedix Inc

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.